Clinical trials: Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Cancer
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00499291
- Testing
- paclitaxel albumin-stabilized nanoparticle formulation, gene expression analysis, laboratory biomarker analysis
- Sponsor
- Eastern Cooperative Oncology Group
Lung Cancer
Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Cediranib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor…
- Trial name
- NCT00795340
- Testing
- carboplatin, cediranib maleate, paclitaxel
- Where
- 19 sites in Brazil, Canada
- Volunteers
- 306 people
- Sponsor
- NCIC Clinical Trials Group
Carcinoma, Non-Small-Cell Lung, Stage IIIA Non-small Cell Lung Cancer
Safety and Efficacy of Vitamin C Infusion in Combination With Local mEHT to Treat Non Small Cell Lung Cancer
This trial studies efficacy and safety of combination of vitamin C infusion with modulated electro-hyperthermia (mEHT) in treatment of non small cell lung cancer patients.Phase I of this clinical study is to find the tolerable…
- Conditions
- Carcinoma, Non-Small-Cell Lung, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- VCONSCLC (NCT02655913)
- Testing
- vitamin C, Modulated Electro-Hyperthermia (mEHT), Supportive care
- Where
- China
- Volunteers
- 97 people
- Sponsor
- Clifford Hospital, Guangzhou, China
Lung Cancer
Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00754923
- Testing
- sorafenib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Lung Cancer
HER-2 Mutations in Tumor Samples From Patients With Advanced Non-Small Cell Lung Cancer Treated on Clinical Trial ECOG-2598
RATIONALE: Collecting samples of tumor tissue from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00896909
- Testing
- gene expression analysis, mutation analysis, polymerase chain reaction
- Volunteers
- 44 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer
Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Conditions
- Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer, Squamous Cell Lung Cancer
- Trial name
- NCT00005838
- Testing
- shark cartilage extract AE-941, cisplatin, vinorelbine tartrate
- Where
- United States
- Volunteers
- 756 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
Trastuzumab Plus Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00003881
- Testing
- trastuzumab, carboplatin, paclitaxel
- Where
- 71 sites in United States, Puerto Rico and 1 more
- Sponsor
- Eastern Cooperative Oncology Group
Lung Cancer
Irinotecan and Gemcitabine in Treating Patients With Recurrent or Progressive Stage III or Stage IV Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as irinotecan and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00182806
- Testing
- gemcitabine hydrochloride, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Roswell Park Cancer Institute
Stage II Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer
Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer
This phase I trial studies the side effects, best dose, and best way to give pembrolizumab when given together with paclitaxel, carboplatin, and radiation therapy in treating patients with stage II-IIIB non-small cell lung…
- Conditions
- Stage II Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer
- Trial name
- NCT02621398
- Testing
- 3-Dimensional Conformal Radiation Therapy, Carboplatin, Intensity-Modulated Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Rutgers, The State University of New Jersey
Lung Diseases, Carcinoma, Non-Small-Cell Lung
Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)
Open-label, non-randomized, phase II multi-centre controlled clinical trial. 51 non-resectable stage IIIA-IIIB non-small cell lung cancer patients will be enrolled in this trial to evaluate the efficacy of the treatment…
- Conditions
- Lung Diseases, Carcinoma, Non-Small-Cell Lung, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
- Trial name
- APOLO (NCT04776447)
- Testing
- Carboplatin, Placlitaxel, Atezolizumab
- Where
- 22 sites in Spain
- Volunteers
- 38 people
- Sponsor
- Fundación GECP
Lung Cancer
Surgery, Gemcitabine, Cisplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00530634
- Testing
- cisplatin, gemcitabine hydrochloride, gene expression analysis
- Volunteers
- 3 people
- Sponsor
- City of Hope Medical Center
Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy for Stage III Non-small Cell Lung Cancer
This randomized phase II trial studies how well positron emission tomography (PET)/computed tomography (CT)-guided radiation therapy works compared to standard radiation therapy in treating patients with stage III non-small cell…
- Conditions
- Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT01507428
- Testing
- 18F-Fluoromisonidazole, Carboplatin, Computed Tomography
- Where
- 31 sites in United States, Canada
- Volunteers
- 138 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer That Overexpresses HER2
Phase II trial to study the effectiveness of trastuzumab in treating patients who have stage IIIB or stage IV non-small cell lung cancer that overexpresses HER2.
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00004883
- Testing
- trastuzumab, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients
RATIONALE: Palliative care may help patients with advanced cancer live more comfortably. PURPOSE: This randomized clinical trial is studying an early intervention palliative care program to see how well it works compared to a…
- Trial name
- NCT00253383
- Testing
- counseling intervention, educational intervention, psychosocial assessment and care
- Where
- 2 sites in United States
- Volunteers
- 329 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
This phase II trial is studying how well sorafenib works in treating patients with stage IIIB or stage IV non-small cell lung cancer.
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT00098540
- Testing
- sorafenib tosylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer, Lung Adenocarcinoma
Peripheral Blood ETASTs for Predicting Efficacy of Chemoimmunotherapy in NSCLC
The goal of this observational study is to explore whether changes in peripheral blood effector tumor antigen-specific T cells (ETASTs) can predict treatment outcomes in patients with advanced non-small cell lung cancer (NSCLC)…
- Conditions
- Non-Small Cell Lung Cancer, Lung Adenocarcinoma, Lung Squamous Cell Carcinoma, Stage IIIB Non-Small Cell Lung Cancer
- Trial name
- NCT07392073
- Testing
- Circulating Tumor-Specific T Cell Nanodetection Technology (CTT-NanoDT)
- Volunteers
- 80 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Lung Cancer
Comfort Level of Two Abdominal Compression Methods Used to Hold Patients Still While Undergoing Stereotactic Body Radiation Therapy for Lung Tumors
RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
- Trial name
- NCT00866086
- Testing
- questionnaire administration, computed tomography, radiation therapy treatment planning/simulation
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Texas Southwestern Medical Center
Adenocarcinoma of the Lung, Large Cell Lung Cancer
S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer
This phase II trial is studying how well erlotinib works in treating patients with advanced primary non-small cell lung cancer. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth
- Conditions
- Adenocarcinoma of the Lung, Large Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer
- Trial name
- NCT00087412
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Lung Cancer
Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01041781
- Testing
- carboplatin, celecoxib, gemcitabine hydrochloride
- Where
- 400 sites in United States
- Volunteers
- 313 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer
S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer
Monoclonal antibodies, such as cetuximab and bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Conditions
- Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer
- Trial name
- NCT00368992
- Testing
- cetuximab, paclitaxel, bevacizumab
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- National Cancer Institute (NCI)